Market Sentiment Around Loss-Making Mesoblast Limited (ASX:MSB), page-3

@itis what itis
I'm curious, does Simply Wall St have a similar disclaimer as that of Yahoo Finance which writes;

"Underlying developments driving MSB’s growth isn’t the focus of this broad overview, though, keep in mind that typically biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments."

The bolding is my emphasis.